The FDA has expanded approval for the cancer drug Enhertu to include treatment of adults with HER2-expressing solid tumors that cannot be surgically removed or have advanced after prior treatment. Enhertu is an antibody drug conjugate that delivers targeted therapy to tumors. The approval was based on Phase 2 studies showing a high overall response rate and duration of response in various types of solid tumors. Common side effects include decreased blood cell levels. AstraZeneca will need to conduct additional post-marketing trials. Analysts believe this decision could lead to broader approvals for other targeted therapies in different types of cancers.
Source link
AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med
